Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


12.07.2021

2 Anticancer Res
1 BJU Int
2 BMC Urol
2 Br J Radiol
1 Cancer Imaging
1 Endocrinology
1 Eur Urol
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Magn Reson Imaging
1 J Urol
1 N Engl J Med
2 Nat Rev Urol
3 PLoS One
1 Prostate
1 Urol Int


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Anticancer Res

  1. HARADA J, Miyata Y, Taima T, Matsuda T, et al
    Stage-specific Embryogenic Antigen-4 Expression in Castration-resistant Prostate Cancer and its Correlation With the Androgen Receptor.
    Anticancer Res. 2021;41:3327-3335.
    PubMed         Abstract available

  2. ERB HHH, Oster MA, Gelbrich N, Cammann C, et al
    Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
    Anticancer Res. 2021;41:3271-3279.
    PubMed         Abstract available


    BJU Int

  3. KREIS K, Horenkamp-Sonntag D, Schneider U, Zeidler J, et al
    Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.
    PubMed         Abstract available


    BMC Urol

  4. MINAGAWA H, Kawai T, Matsumoto A, Makino K, et al
    Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation.
    BMC Urol. 2021;21:8.
    PubMed         Abstract available

  5. WANG X, Zhang Y, Zhang F, Ji Z, et al
    Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation.
    BMC Urol. 2021;21:3.
    PubMed         Abstract available


    Br J Radiol

  6. KIM Y, Park JJ, Kim CK
    Blood oxygenation level-dependent MRI at 3T for differentiating prostate cancer from benign tissue: a preliminary experience.
    Br J Radiol. 2021 Jul 8:20210461. doi: 10.1259/bjr.20210461.
    PubMed         Abstract available

  7. GIGANTI F, Allen C, Stavrinides V, Stabile A, et al
    Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?
    Br J Radiol. 2021 Jul 8:20210321. doi: 10.1259/bjr.20210321.
    PubMed         Abstract available


    Cancer Imaging

  8. HE D, Wang X, Fu C, Wei X, et al
    MRI-based radiomics models to assess prostate cancer, extracapsular extension and positive surgical margins.
    Cancer Imaging. 2021;21:46.
    PubMed         Abstract available


    Endocrinology

  9. LUDWIG M, Rajvansh R, Drake JM
    Emerging Role of Extracellular Vesicles in Prostate Cancer.
    Endocrinology. 2021 Jul 7. pii: 6316765. doi: 10.1210.
    PubMed         Abstract available


    Eur Urol

  10. MARSDEN T, Ahmed HU, Emberton M
    An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, an
    Eur Urol. 2021 Jul 1. pii: S0302-2838(21)01817.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  11. BERTHOLD J, Khamfongkhruea C, Petzoldt J, Thiele J, et al
    First-in-human validation of CT-based proton range prediction using prompt gamma imaging in prostate-cancer treatments.
    Int J Radiat Oncol Biol Phys. 2021 Jul 3. pii: S0360-3016(21)00843.
    PubMed         Abstract available


    Int J Urol

  12. MIYAMOTO S, Goto K, Honda Y, Terada H, et al
    Tumor contact length of prostate cancer determined by a three-dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence.
    Int J Urol. 2021 Jul 5. doi: 10.1111/iju.14633.
    PubMed         Abstract available


    J Magn Reson Imaging

  13. MONTOYA PEREZ I, Merisaari H, Jambor I, Ettala O, et al
    Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer.
    J Magn Reson Imaging. 2021 Jul 5. doi: 10.1002/jmri.27811.
    PubMed         Abstract available


    J Urol

  14. PURYSKO AS, Bullen J, Valdez R, Auschof E, et al
    Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection With MRI: A Matched Cohort Study.
    J Urol. 2021 Jul 6:101097JU0000000000001932. doi: 10.1097/JU.0000000000001932.
    PubMed         Abstract available


    N Engl J Med

  15. EKLUND M, Jaderling F, Discacciati A, Bergman M, et al
    MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.
    PubMed         Abstract available


    Nat Rev Urol

  16. WOLF P, Alzubi J, Gratzke C, Cathomen T, et al
    The potential of CAR T cell therapy for prostate cancer.
    Nat Rev Urol. 2021 Jul 8. pii: 10.1038/s41585-021-00488.
    PubMed         Abstract available

  17. KIM JS, Galvao DA, Newton RU, Gray E, et al
    Publisher Correction: Exercise-induced myokines and their effect on prostate cancer.
    Nat Rev Urol. 2021 Jul 6. pii: 10.1038/s41585-021-00501.
    PubMed        


    PLoS One

  18. JIANG X, Renkema H, Smeitink J, Beyrath J, et al
    Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
    PLoS One. 2021;16:e0254315.
    PubMed         Abstract available

  19. SALMI F, Maachi F, Tazzite A, Aboutaib R, et al
    Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.
    PLoS One. 2021;16:e0254101.
    PubMed         Abstract available

  20. RUNDLE AG, Sadasivan SM, Chitale DA, Gupta NS, et al
    Racial differences in the systemic inflammatory response to prostate cancer.
    PLoS One. 2021;16:e0252951.
    PubMed         Abstract available


    Prostate

  21. LAUNER BM, Lloyd GL
    Sociodemographic index and global trends in prostate cancer: 1990-2017.
    Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
    PubMed         Abstract available


    Urol Int

  22. TIAN B, Chunxiang E, Xiang Y, Teng P, et al
    Long Noncoding RNA LIPE-AS1 Drives Prostate Cancer Progression by Functioning as a Competing Endogenous RNA for microRNA-654-3p and Thereby Upregulating Hepatoma-Derived Growth Factor.
    Urol Int. 2021 Jul 7:1-16. doi: 10.1159/000516676.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: